Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
๐ฉบ Protocol Summary
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
Primary Research Facility: Arkansas Childrens Hospital (Little Rock, Arkansas)
๐ Basic Study Criteria & Logistics Checklist
0 of 3 CheckedReview these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).
๐ Primary Site Map
Site: Arkansas Childrens Hospital โ Little Rock, Arkansas
๐ All Participating Trial Locations (38 Sites)
Multi-Center TrialThis protocol is enrolling participants across multiple clinical centers:
๐ Print Doctor Discussion Sheet
Preview and print a 1-page summary with 5 tailored questions for your physician.
๐ฐ Clinical Trial Costs & Insurance Coverage
Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act ยง 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.
๐ก Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.